Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

(2023) Fabrice André et al.   LANCET

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

(2022) Binliang Liu et al.   Cancer Medicine

Landmark trials in the medical oncology management of metastatic breast cancer

(2021) Pei Lu et al.   SEMINARS IN ONCOLOGY

Dissecting the biological heterogeneity of HER2-positive breast cancer

(2021) Francesco Schettini et al.   BREAST

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

(2019) Sherene Loi et al.   LANCET ONCOLOGY

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial

(2019) R Barroso-Sousa et al.   ANNALS OF ONCOLOGY

Prevalence and role of HER2 mutations in cancer

(2019) Emiliano Cocco et al.   PHARMACOLOGY & THERAPEUTICS

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

(2018) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

(2018) Funda Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

(2018) Sarah Croessmann et al.   CLINICAL CANCER RESEARCH

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

(2018) Emiliano Cocco et al.   Science Signaling

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2017) Fei Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

(2016) W.-J. Zuo et al.   CLINICAL CANCER RESEARCH

Genomic Characterization of Primary Invasive Lobular Breast Cancer

(2016) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer

(2015) Xuli Meng et al.   AMINO ACIDS

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers

(2015) Wenhsiang Wen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

(2015) Roberto Salgado et al.   JAMA Oncology

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

(2014) N. A. O'Brien et al.   CLINICAL CANCER RESEARCH

Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

(2014) Siraj M. Ali et al.   JOURNAL OF CLINICAL ONCOLOGY

Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells

(2013) Yuji Sato et al.   CANCER SCIENCE

Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

(2013) B. N. Rexer et al.   CLINICAL CANCER RESEARCH

HER1R497K andHER2I655V Polymorphisms Are Linked to Development of Breast Cancer

(2013) Naglaa R. AbdRaboh et al.   DISEASE MARKERS

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

(2010) Kathleen A. Cronin et al.   CANCER INVESTIGATION

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY